RheaVita

About:

RheaVita is a pharmaceutical company developing continuous freeze-drying technology for biopharmaceutical products.

Website: https://www.rheavita.com

Twitter/X: rheavita

Top Investors: PMV, Novalis Biotechnology Incubation

Description:

RheaVita is a pharmaceutical company developing continuous freeze-drying technology for biopharmaceutical products. The company technology integrates all freeze-drying process step unit operations in a continuous production line with the constant infeed of products and the concomitant outfeed of the dried product. Its manufacturing approach avoids scale-up issues, reduces cycle times, allows fast product development, reduces time-to-market, lowers production costs, makes use of smaller manufacturing installations, requires less clean room space, provides improved quality assurance (100% inspection with inherent potential for real-time-release) and leads to improved and uniform product quality and process uniformity.

Total Funding Amount:

2.5M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Zwijnaarde, Oost-Vlaanderen, Belgium

Founded Date:

2018-01-01

Contact Email:

info(AT)rheavita.com

Founders:

Jos Corver, Thomas De Beer

Number of Employees:

11-50

Last Funding Date:

2021-06-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai